Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,591 recruiting studies in this area right now.
By phase
- Not applicable9,784
- Phase 24,449
- Phase 12,735
- Phase 1/Phase 21,686
- Phase 31,394
- Phase 2/Phase 3280
- Phase 4263
Top conditions
- Breast Cancer1,225
- Cancer661
- Prostate Cancer653
- Colorectal Cancer491
- Lung Cancer424
- Ovarian Cancer338
- Multiple Myeloma332
- Gastric Cancer296
- Acute Myeloid Leukemia292
- Pancreatic Cancer289
- Hepatocellular Carcinoma283
- Solid Tumor256
- Advanced Solid Tumor255
- Cervical Cancer232
- Head and Neck Cancer227
- Endometrial Cancer206
- Advanced Solid Tumors193
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center450
- Fudan University312
- Sun Yat-sen University291
- Memorial Sloan Kettering Cancer Center288
- National Cancer Institute (NCI)286
- Mayo Clinic240
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center147
- AstraZeneca134
- University Health Network, Toronto125
Where studies are running
- California1,425
- Texas638
- Arizona512
- Florida448
- Alabama420
- New York408
- Massachusetts343
- Maryland330
- New Jersey269
- Pennsylvania242
Recruiting studies20,591 total
- NCT04998552Recruiting
CyberKnife radiation for certain pancreatic cancer patients after chemotherapy
This trial studies how safe CyberKnife is when used to treat some borderline resectable or locally advanced pancreatic cancers after chemotherapy. It may help patients by targeting the tumor with precise radiation, while researchers closely watch for side effects.
Pennington, New JerseyAges 18 years+ - NCT05154305Recruiting
Rehab program for children after acute cancer treatment
This trial studies a multidisciplinary rehabilitation program to help children and teens recover and improve their physical fitness after acute cancer treatment. It may be useful if you’re not currently on cancer medicines and are in the follow-up period.
GhentAges 8–21 - NCT04733729Recruiting
COVID-19 in blood cancer patients
This study looks at COVID-19 in people who have (or have had) blood cancers and are positive for SARS‑CoV‑2. It may help doctors understand how COVID-19 affects people with blood cancers and guide care.
BresciaAges 18–99 - NCT04991948RecruitingPhase 1
Testing pembrolizumab after CYAD-101 plus FOLFOX in colon cancer
This early-phase study tests whether adding pembrolizumab after CYAD-101 and FOLFOX chemotherapy can help treat metastatic colon or rectal cancer. It is mainly looking for safety and signs of how well the treatment works in people whose cancer has not responded to prior therapy.
Jacksonville, FloridaAges 18 years+ - NCT04838652RecruitingPhase 2
Pembrolizumab with salvage chemotherapy for Hodgkin lymphoma
This Phase 2 study tests whether pembrolizumab combined with salvage (second-line) chemotherapy can treat people whose classical Hodgkin lymphoma has either come back after initial treatment or did not respond to initial treatment. You may benefit if you have first-relapsed or refractory classical Hodgkin lymphoma and meet other study rules.
CologneAges 18–65 - NCT05043688RecruitingPhase 3
Camrelizumab with chemo before surgery versus chemo-radiation
This Phase 3 trial compares two ways of treating resectable esophageal squamous cell cancer: (1) camrelizumab plus chemotherapy before surgery versus (2) chemo-radiation. It aims to see whether adding camrelizumab before surgery can improve outcomes for people who are planned to have their tumor surgically removed.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04997993RecruitingPhase 1
Leflunomide for PTEN-altered or HER2-negative metastatic cancers
This Phase 1 trial studies whether leflunomide can slow or control advanced (metastatic) cancers in people whose tumors have specific PTEN changes or who have HER2-negative breast cancer. It’s primarily a safety-and-dosing study, but it may offer benefit if your cancer matches the tumor marker requirements.
New York, New YorkAges 18 years+ - NCT05075512RecruitingPhase 2
Anlotinib with fulvestrant for advanced, HR-positive, HER2-negative breast cancer
This trial studies whether adding anlotinib (a targeted medicine) to fulvestrant (a hormone-blocking injection) can improve outcomes for people with advanced HR-positive, HER2-negative breast cancer. It focuses on safety and effectiveness when cancer has returned or progressed after hormone treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT04866641RecruitingPhase 1
Early safety study of T-1201 for advanced solid tumors
This Phase 1 study tests how safe T-1201 (an injection) is in people with advanced solid tumors that are not responding to standard treatment. It mainly looks at side effects and tolerability, and it may offer a treatment option if other options are no longer working.
Kaohsiung CityAges 20 years+ - NCT04986423RecruitingPhase 2
Add ZEN003694 to enzalutamide for resistant prostate cancer
This Phase 2 study tests whether adding ZEN003694 to enzalutamide works better than enzalutamide alone in men whose prostate cancer has spread and is no longer controlled by hormone lowering treatments. It focuses on people who either did not respond well to abiraterone (poor responders) or did respond (responders), then compares outcomes between treatment groups.
Los Angeles, CaliforniaAges 18 years+ - NCT04865939RecruitingPhase 3
Gemcitabine treatment compared with bladder wash in UTUC surgery
This Phase 3 trial studies whether using gemcitabine (a chemotherapy medicine) in the urinary tract better prevents cancer from coming back than using a simple water wash. It involves people with upper tract urothelial carcinoma who are having curative surgery to remove the affected ureter or kidney tube.
Dallas, TexasAges 18–90 - NCT04737889RecruitingPhase 2
Rituximab plus lenalidomide, methotrexate, and temozolomide for brain lymphoma
This Phase 2 study tests a combination treatment to shrink primary central nervous system lymphoma that starts in the brain, spinal cord, meninges, or eye. It may help patients who have not had anti-cancer treatment yet, but it requires specific cancer type and health conditions.
Zhengzhou, HenanAges 18–70 - NCT04762862Enrolling by invitation
Testing gene-guided cancer treatment changes in advanced tumors
This trial studies whether measuring changes in your tumor’s genes (from pangenomic quantitative testing) can help guide cancer treatment when standard cures aren’t available. It may help doctors choose therapies based on what your tumor shows.
NiceAges Any age - NCT04945330Recruiting
Study for NTRK fusion cancers taking larotrectinib
This trial is for people with advanced or returning solid tumors that have specific gene changes called NTRK gene fusions. It looks at patients who are already being treated with larotrectinib as part of normal care, to understand this treatment in real life.
Multiple LocationsAges Any age - NCT05228106Recruiting
PSMA scan using 68Ga-PSMA-617 PET/CT
This study looks at a PSMA-targeted PET/CT scan using 68Ga-PSMA-617 for tumors that show a specific marker (PSMA). It’s meant to help confirm or evaluate suspected or known PSMA-expressing tumors in real-life clinical practice.
Sherbrooke, QuebecAges Any age - NCT05203172RecruitingPhase 4
Continue encorafenib and binimetinib after prior trial benefit
This study lets people who previously took encorafenib and binimetinib continue those same medicines if they are benefiting and side effects are not severe. It’s meant to help participants stay on treatment safely while the original trial is completed.
Phoenix, ArizonaAges 18 years+ - NCT05096715RecruitingPhase 1
Testing atezolizumab plus bevacizumab with SBRT for advanced liver cancer
This Phase 1 trial tests how well a combination treatment works for liver cancer that cannot be removed with surgery or other local treatments. It combines two immune/targeted medicines with a focused type of radiation (SBRT) to control the tumors.
Boston, MassachusettsAges 18 years+ - NCT05024552RecruitingPhase 1
Vyxeos plus gilteritinib for certain relapsed AML
This Phase 1 trial studies whether combining Vyxeos (a chemotherapy) with gilteritinib (a targeted drug) can treat AML that has come back or hasn’t responded well, specifically AML with certain FLT3 mutations. If it works, it could improve chances of controlling the leukemia.
Tampa, FloridaAges 18 years+ - NCT05057052RecruitingPhase 2
Freezing liver tumors with immunotherapy and a pill drug
This Phase 2 trial tests whether freezing (cryoablation) plus sintilimab (an immune system medicine) and regorafenib (a pill) can shrink colorectal cancer that has spread to the liver. It is for people whose cancer has come back or progressed after at least two prior chemotherapy treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04793633Enrolling by invitation
Testing a noninvasive way to collect pancreatic cells early
This study tests LINFU™, a noninvasive method to collect pancreatic cells to help detect pancreatic cancer earlier. You may be invited if you’re at higher risk or you have concerning symptoms and planned pancreas/bile testing (like EUS or CT).
Sarasota, FloridaAges 18–90 - NCT04740398RecruitingPhase 1
CBP-1008 for advanced solid tumors that standard therapy failed
This Phase 1 study tests CBP-1008, a new experimental treatment, in people with advanced solid cancers that either worsened after standard treatment or for which no standard option exists. It may help doctors learn the safest dose and whether it shows signs of benefit in specific tumor types.
Beijing, Beijing MunicipalityAges 18–70 - NCT04886401Recruiting
Study predicting response to pembrolizumab in advanced lung cancer
This study looks back at prior treatment to learn which patients with advanced non-small cell lung cancer (NSCLC) are more likely to respond to pembrolizumab, an immune therapy given up front. The results may help doctors better predict who benefits from this treatment.
BrestAges Any age - NCT04760327RecruitingPhase 2
Electrotherapy for returning gynecologic cancers
This Phase 2 study tests electrotherapy (a way to help treatment reach tumor cells) for gynecologic cancers that have come back after standard treatments were used up. You may be considered if your overall health allows anesthesia and if certain cancer spread and medical safety issues do not apply.
LjubljanaAges 18–105 - NCT04859465RecruitingPhase 2
Paclitaxel plus doxorubicin for advanced, unresectable angiosarcoma
This Phase 2 trial tests a chemotherapy combination (paclitaxel and liposomal doxorubicin) for people with advanced angiosarcoma that cannot be removed by surgery. It is meant for cases where standard treatment either did not work or was too hard to tolerate, and it aims to shrink tumors and control the disease.
Guangzhou, GuangdongAges 18–70
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,591 recruiting oncology studies from the U.S. registry right now, out of 31,235 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.